What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2026-05-29 compared with 2025-12-03 · 54 added, 17 removed, 38 unchanged (65% of the section changed)

8 unchanged sentences

2804) (the "MDL") is pending in the U.S.

District Court for the Northern District of Ohio and includes approximately 230 cases with claims against the Company as of December 1, 2025.

In addition, there are approximately 13 other opioid-related cases against the Company and its subsidiaries pending in U.S.

state and federal courts and Canadian courts as of December 1, 2025.

The non-MDL case citations are listed on Exhibit 99.1 to this Quarterly Report on Form 10-Q.

District Court for the Northern District of Ohio and includes approximately 130 cases with claims against the Company as of May 22, 2026.

In addition, the following 13 other opioid-related cases against the Company and its subsidiaries were pending in U.S.

state and federal courts and Canadian courts as of May 22, 2026:

Baby Doe 1, et al.

Allergan Finances, LLC, et al., U.S.

Tenn., 4/29/25;

Marshall Cty.

of Educ., et al.

Cephalon, Inc., et al., U.S.

Va., 10/28/24;

CVS Pharm., Inc., et al., Nev.

Ct., Nye Cty., 2/26/24;

CVS Pharm., Inc., et al., Ky.

Ct., Perry Cty., 12/11/23;

City of Grande Prairie, et al.

Apotex Inc., et al., Alta.

King's Bench Ct., Calgary Jud.

Ctr., 4/27/23;

Lac La Ronge Indian Band, et al.

Apotex Inc., et al., Sask.

King's Bench Ct., Prince Albert Jud.

Ctr., 3/17/23;

Commonwealth of Pennsylvania ex rel.

Allegheny Cty.

Att'y Stephen A.

CVS Ind., LLC, et al., Pa.

Pl., Delaware Cty., 8/8/22;

Baby Doe, et al., ex rel.

Their Guardian Ad Litem v.

Endo Health Sols., Inc., et al., U.S.

Tenn., 8/3/22;

Paynter ex rel.

Minor Child(ren) Z.N.B.

McKesson Corp., et al., W.

Ct., Kanawha Cty., 3/28/22;

Blankenship ex rel.

Minor Child Z.D.B.

McKesson Corp., et al., W.

Ct., Kanawha Cty., 1/14/22;

Amneal Pharm., LLC, et al., Miss.

Dist., Hinds Cty.

Ct., 5/15/20;

d/b/a Parkland Health & Hosp.

Sys., et al., v.

Amneal Pharm., LLC, et al., Tex.

Ct., 152nd Jud.

Dist., Harris Cty., 11/20/19;

Ctr., Inc., et al.

Sackler, et al., Fla.

Ct., 17th Jud.

Cir., Broward Cty., 9/16/19.

DOJ Opioid Civil Litigation:

2 unchanged sentences

of DE, 12/22/20.

Settlement of Certain Opioid-Related Matters:

As described in more detail in Note 6 to our Condensed Consolidated Financial Statements, the Company accrued a liability of approximately $3.3 billion in fiscal year 2023 for certain opioid-related settlements.

As of January 31, 2025, all of the accrued liability has been paid.

Certain federally recognized Native American tribes have until February 24, 2026 to join the settlement.

Opioid-Related Securities Class Actions:

et al., USDC, Dist.

of DE, 1/20/21 and Martin v.

et al., USDC , Dist.

of DE, 3/5/21, consolidated into In re Walmart Inc.

Securities Litigation , USDC, Dist.

of DE, 5/11/21;

In re Walmart Inc.

Securities Litigation, USCCA, 3d Cir., 4/29/24.

False Claims Act Litigation:

8 unchanged sentences

and Abusubih & Others v Asda Stores limited (KB-2022-003240).

Federal Trade Commission and State Attorneys General Driver Platform Litigation:

Federal Trade Commission, et al.

Cal., 2/26/26 .

Mexico Antitrust Matter:

14 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings